- Award ID(s):
- 1556370
- NSF-PAR ID:
- 10334506
- Date Published:
- Journal Name:
- Advanced Devices & Instrumentation
- Volume:
- 2021
- ISSN:
- 2767-9713
- Page Range / eLocation ID:
- 1 to 30
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
Ingestible capsule systems continue to evolve to overcome drawbacks associated with traditional gastrointestinal (GI) diagnostic and therapeutic processes, such as limitations on which sections of the GI tract can be accessed or the inability to measure local biomarker concentrations. We report an integrated capsule sensing system, utilizing a hybrid packaging scheme coupled with triglyceride film-coated capacitive sensors, for measuring biochemical species present in the duodenum, such as pancreatic lipase and bile acids. The system uses microfabricated capacitive sensors interfaced with a Bluetooth low-energy (BLE)-microcontroller, allowing wireless connectivity to a mobile app. The triglyceride films insulate the sensor surface and react either with 0.01–1 mM lipase via hydrolysis or 0.07–7% w/v bile acids via emulsification in simulated fluids, leading to measurable changes in capacitance. Cross reactivity of the triglyceride films is evaluated in both phosphate buffered saline (PBS) as well as pancreatic trypsin solutions. The film morphology is observed after exposure to each stimulus to better understand how these changes alter the sensor capacitance. The capsule utilizes a 3D-printed package coated with polymers that remain intact in acid solution (mimicking gastric conditions), then dissolve at a duodenum-mimicking neutral pH for triggered opening of the sensing chamber from which we can subsequently detect the presence of pancreatic lipase. This device strategy represents a significant step towards using embedded packaging and triglyceride-based materials to target specific regions of the GI tract and sensing biochemical contents for evaluating gastrointestinal health.more » « less
-
The integration of an ingestible dosage form with sensing, actuation, and drug delivery capabilities can enable a broad range of surgical‐free diagnostic and treatment strategies. However, the gastrointestinal (GI) tract is a highly constrained and complex luminal construct that fundamentally limits the size of an ingestible system. Recent advancements in mesoscale magnetic crawlers have demonstrated the ability to effectively traverse complex and confined systems by leveraging magnetic fields to induce contraction and bending‐based locomotion. However, the integration of functional components (e.g., electronics) in the proposed ingestible system remains fundamentally challenging. Herein, the creation of a centralized compartment in a magnetic robot by imparting localized flexibility (MR‐LF) is demonstrated. The centralized compartment enables MR‐LF to be readily integrated with modular functional components and payloads, such as commercial off‐the‐shelf electronics and medication, while preserving its bidirectionality in an ingestible form factor. The ability of MR‐LF to incorporate electronics, perform drug delivery, guide continuum devices such as catheters, and navigate air–water environments in confined lumens is demonstrated. The MR‐LF enables functional integration to create a highly integrated ingestible system that can ultimately address a broad range of unmet clinical needs. An interactive preprint version of the article can be found at
https://doi.org/10.22541/au.166274072.23086985/v1 . -
Abstract Ingestible biomedical devices that diagnose, prevent, or treat diseases has been a dream of engineers and clinicians for decades. The increasing apparent importance of gut health on overall well‐being and the prevalence of many gastrointestinal diseases have renewed focus on this emerging class of medical devices. Several prominent examples of commercially successful ingestible medical devices exist. However, many technical challenges remain before ingestible medical devices can achieve their full clinical potential. This Minireview summarizes recent discoveries in this interdisciplinary topic including novel materials, advanced materials processing techniques, and select examples of integrated ingestible electromechanical systems. After a brief historical perspective, these topics will be reviewed with a dedicated focus on advanced functional materials and fabrication strategies in the context of clinical translation and potential regulatory considerations. Future perspectives, challenges, and opportunities related to ingestible medical devices will also be summarized.
-
Abstract Hydrogen sulfide (H2S) is a gaseous inflammatory mediator and important signaling molecule for maintaining gastrointestinal (GI) homeostasis. Excess intraluminal H2S in the GI tract has been implicated in inflammatory bowel disease and neurodegenerative disorders; however, the role of H2S in disease pathogenesis and progression is unclear. Herein, an electrochemical gas‐sensing ingestible capsule is developed to enable real‐time, wireless amperometric measurement of H2S in GI conditions. A gold (Au) three‐electrode sensor is modified with a Nafion solid‐polymer electrolyte (Nafion‐Au) to enhance selectivity toward H2S in humid environments. The Nafion‐Au sensor‐integrated capsule shows a linear current response in H2S concentration ranging from 0.21 to 4.5 ppm (
R 2= 0.954) with a normalized sensitivity of 12.4% ppm−1when evaluated in a benchtop setting. The sensor proves highly selective toward H2S in the presence of known interferent gases, such as hydrogen (H2), with a selectivity ratio of H2S:H2= 1340, as well as toward methane (CH4) and carbon dioxide (CO2). The packaged capsule demonstrates reliable wireless communication through abdominal tissue analogues, comparable to GI dielectric properties. Also, an assessment of sensor drift and threshold‐based notification is investigated, showing potential for in vivo application. Thus, the developed H2S capsule platform provides an analytical tool to uncover the complex biology‐modulating effects of intraluminal H2S. -
Abstract Current systemic therapies for inflammatory gastrointestinal (GI) disorders are unable to locally target lesions and have substantial systemic side effects. Here, a compact mesoscale spring actuator capable of delivering an anchoring drug deposit to point locations in the GI tract is demonstrated. The mechanism demonstrated here is intended to complement existing ingestible capsule‐based sensing and communication technologies, enabling treatment based on criteria such as detected GI biomarkers or external commands. The 3D‐printed actuator has shown on command deployment in 14.1 ± 3.0 s, and a spring constant of 25.4 ± 1.4 mN mm−1, sufficient to insert a spiny microneedle anchoring drug deposit (SMAD) into GI tissue. The complementary SMAD showed a 22‐fold increase in anchoring force over traditional molded microneedles, enabling reliable removal from the actuator and robust prolonged tissue attachment. The SMAD also showed comparable drug release characteristics (
R 2 = 0.9773) to penetrating molded microneedles in agarose phantom tissue with a drug spread radius of 25 mm in 168 h. The demonstrated system has the potential to enable on command delivery and anchoring of drug‐loaded deposits to the GI mucosa for sustained treatment of GI inflammation while mitigating side effects and enabling new options for treatment.